Healing & recovery · Evidence comparison

TB-500 vs GHK-Cu

Two peptides marketed for tissue repair — but their evidence lives in completely different places.

TB-500

BAccelerates muscle, tendon, and ligament healing (the use it's sold for)
vs

GHK-Cu

STopical GHK-Cu improves skin appearance (wrinkles, density, firmness)

Headline claim shown. Grades are claim-specific — see the full breakdown below.

The evidence, side by side

Every graded claim from each brief. Grades are read straight from the source-checked briefs — one molecule can be strong for one use and weak for another.

Healing / recovery

TB-500

Evidence grades

B
Accelerates muscle, tendon, and ligament healing (the use it's sold for)Mostly anecdotal
S
Full-length thymosin beta-4 (NOT TB-500) aids corneal / ocular wound healingLimited human evidence
C
Is a proven injectable recovery aid for peopleUnsupported

Skin / wound healing / anti-aging

GHK-Cu

Evidence grades

S
Topical GHK-Cu improves skin appearance (wrinkles, density, firmness)Limited human evidence
A
Topical GHK-Cu accelerates wound healingMostly preclinical
A
Stimulates hair growth (topical)Mostly preclinical
B
Injectable GHK-Cu is a proven systemic anti-aging / healing therapyMostly anecdotal

Regulatory status at a glance

TB-500

Not FDA-approved for human use. Listed by the FDA as 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; removed from compounding 'Category 2' in April 2026 after nominations were withdrawn — which does NOT by itself authorize compounding. On the July 2026 FDA advisory committee agenda. Prohibited at all times in sport by WADA. Currently sold gray-market as 'research only.'

GHK-Cu

Topical GHK-Cu (as Copper Tripeptide-1) is a legal OTC cosmetic ingredient widely used in skincare products, and can be physician-prescribed as a compounded topical. Injectable GHK-Cu is in FDA compounding Category 2 (significant safety concerns) and cannot be legally compounded for injection; it is scheduled for February 2027 PCAC review. Not FDA-approved as a drug for any indication.

Key differences

  • GHK-Cu's topical skin improvement is graded S (real human data); TB-500's marketed recovery use is graded B (anecdotal).
  • TB-500's only strong human evidence belongs to the full-length protein thymosin beta-4, not the fragment sold as TB-500.
  • Topical GHK-Cu is a legal cosmetic; injectable GHK-Cu and TB-500 are unapproved and not legally compoundable for injection.

The bottom line

GHK-Cu has an actual human-evidence grade for topical skin use; TB-500's marketed injectable use rests on anecdote, with its real research attached to a different molecule. We don't recommend either — we show where the proof actually is.

PeptideIQ Base does not recommend, rank, or endorse any peptide, dose, or product. We grade the strength of the evidence so you can read it for yourself.

See every peptide, graded on one page

The Peptide Evidence Report Card grades all our peptides S+ to C on the strength of the human evidence. Research only — no hype, never a recommendation.

Get the report card →